A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.
about
SYK is a critical regulator of FLT3 in acute myeloid leukemiaMolecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted TherapyTropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancerAn overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatmentValidation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITDSecondary mutations as mediators of resistance to targeted therapy in leukemiaFLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitationsReversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cellsLestaurtinib inhibits histone phosphorylation and androgen-dependent gene expression in prostate cancer cellsEvaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancerTargeting oncoprotein stability overcomes drug resistance caused by FLT3 kinase domain mutationsTofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1).Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinibDiscovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia.Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITDToxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference.Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer TherapyPatterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemiaMolecular therapy for acute myeloid leukaemia.Challenges in treating older patients with acute myeloid leukemia.Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemiaTreatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.Crystal structures of PRK1 in complex with the clinical compounds lestaurtinib and tofacitinib reveal ligand induced conformational changes.Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma.Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis.The Biology and Targeting of FLT3 in Pediatric Leukemia.Dependence receptor TrkC is a putative colon cancer tumor suppressor.Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias.FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes.FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasmCells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy.Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells.Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study.The Future of Targeting FLT3 Activation in AML.
P2860
Q24337247-02A66EBD-B782-4989-A4A1-85A5119C393CQ26749870-53641CD9-D3D5-49E0-8592-64EC305DB18FQ26774713-026BBB84-87DC-4DCF-B5DA-6B47B3BFD7EBQ27027207-2B8EA869-63B1-43BD-BB59-36C9EE656C7BQ27851767-22353883-DD69-4B06-A691-D5CD6D840737Q27852087-3A584904-60D3-4204-AD93-42C2E779112AQ28087213-0A2F6D44-D08C-40C7-8E33-88A61E9214F9Q28289859-8D051858-58A6-47C6-B65E-5C64A66D5125Q28477269-4882CBB1-F30B-4564-AC75-CCF06440D2D3Q28482432-36DF6D4B-2E27-4CEF-B40B-5DF2F1FF9D7FQ28538435-409DB151-874E-456A-B01A-004D28361DA4Q28539032-D7E29D3F-2CBA-442F-8407-2963533E63DDQ30313903-62B21F51-A5DA-47B1-AA02-549B27CF0919Q33402522-B035C97F-D167-4951-AB67-D49F972A6449Q33749036-5572386B-5A66-4EC2-A50B-38E5EC563D7AQ33767026-2006E640-4448-4507-A3B1-C9E1E8AF3BDEQ33798909-3B1D060F-E91D-4A15-BE2F-893C5D259BE8Q33801811-96A33A33-FF04-4F02-97F1-5DAF02A424E7Q33813439-30ADF8C0-6955-468C-AD26-EEBAE46A8AD5Q33859472-03C98419-2BD7-4710-AE04-B4A4B3501A40Q33913329-591BAA73-5323-452B-B17C-B6074CF8AD42Q33925672-40A1E2E3-A5D0-4950-A686-36C7834658D5Q33985549-68FEAEFE-7CE7-4242-9D1F-277CD58DECADQ34004131-FACDD5CF-2D6A-43C2-9599-4017FCF2B4DEQ34011740-2254948F-A712-4D0C-A367-6C7AF07F86E6Q34028255-1E1005EE-7CA1-4F3F-A498-7CEF6E2AF9C1Q34055511-646F9286-98FA-4127-A4E5-005B337F35E6Q34095013-B15ED431-D3DE-4990-B514-736F79566B0FQ34097586-A5F3AFCF-C164-482B-9DE0-221A0486571AQ34104338-CBFD4838-24E2-4A28-9DB2-94304952D0E8Q34218232-96FE7BA6-EEC9-4EAD-8EDE-B2457C0FDA38Q34229555-15DB0783-73FE-402C-9BEC-B53BFC84852DQ34323861-287CBCE5-C8A1-4B63-A544-5B731E1472A2Q34335004-471CED55-F516-47BA-9C90-538D22F8B140Q34350591-84D7C858-26CE-48EF-B109-C162A92A5F60Q34408941-C4EE3FEC-8307-475C-8B9A-EA12E75B7180Q34450478-49755759-30F2-4399-AD93-04F0DF768D12Q34501206-8EC245DD-2B98-4B25-9033-7EAAE57B3AFEQ34549193-110E033F-22C3-46FF-9290-5718AC96DD80Q34555386-A257F53E-5F25-49B6-9F7F-C0373841AAD0
P2860
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
A phase 2 trial of the FLT3 in ...... it for intensive chemotherapy.
@ast
A phase 2 trial of the FLT3 in ...... it for intensive chemotherapy.
@en
A phase 2 trial of the FLT3 inhibitor lestaurtinib
@nl
type
label
A phase 2 trial of the FLT3 in ...... it for intensive chemotherapy.
@ast
A phase 2 trial of the FLT3 in ...... it for intensive chemotherapy.
@en
A phase 2 trial of the FLT3 inhibitor lestaurtinib
@nl
prefLabel
A phase 2 trial of the FLT3 in ...... it for intensive chemotherapy.
@ast
A phase 2 trial of the FLT3 in ...... it for intensive chemotherapy.
@en
A phase 2 trial of the FLT3 inhibitor lestaurtinib
@nl
P2093
P921
P1433
P1476
A phase 2 trial of the FLT3 in ...... it for intensive chemotherapy.
@en
P2093
Alan K Burnett
Donald Small
Mark J Levis
Raj Chopra
Richard Clark
Sam Agrawal
Steven Knapper
Tim Littlewood
W Jonathan Kell
P304
P356
10.1182/BLOOD-2006-04-015560
P407
P577
2006-07-20T00:00:00Z